Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm of advanced-stage non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The aim of this study was to evaluate the effectiveness and tolerance of ICIs in a real-world patient population and to investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shijia, Pease, Daniel F, Kulkarni, Amit A, Kumar, Manoj, Shanley, Ryan M, Xu, Beibei, Joshi, Shilvi P, Patel, Manish R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237437/
https://www.ncbi.nlm.nih.gov/pubmed/34248362
http://dx.doi.org/10.1177/11795549211004489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237437/
https://www.ncbi.nlm.nih.gov/pubmed/34248362
http://dx.doi.org/10.1177/11795549211004489

Ejemplares similares